Computer-Aided Drug Design: SBDD, LBDD, QSAR, Pharmacophores and ADMET
Chemical databases, receptor-ligand interactions, docking and SBDD, LBDD, QSAR, pharmacophores, drug-likeness and ADMET prediction for CSIR NET LS-BT.
- 21 min
On this page · 14 sections
Prerequisites
- Molecular Modelling, Dynamics and Protein Structure Prediction — force fields, minimisation and the structures that docking needs.
- Enzymes: Catalysis, Kinetics, Regulation and Isozymes — \(K_m\), inhibition types and active sites: the language of target binding.
- Chemical Bonds, Stabilising Interactions and Biophysical Chemistry — hydrogen bonds, ionic and hydrophobic interactions, and binding free energy.
The Hook: Reading a Pocket
How CSIR NET asks it. New topic in the revised LS-BT syllabus, so there are no past CSIR papers. Expect Part B on which approach fits which situation (structure known or not), what a pharmacophore or a QSAR descriptor is, and Lipinski’s rule. Expect Part C on \(\Delta G\) from \(K_d\), a Hansch-type prediction, a Tanimoto coefficient, an enrichment factor, or counting rule-of-five violations.
The Discovery Pipeline and Where Computation Sits
graph LR
T["Target identification
and validation"] --> H["Hit finding
HTS, virtual screening,
fragments"]
H --> L["Hit to lead"]
L --> O["Lead optimisation
potency, selectivity,
ADMET"]
O --> P["Preclinical
studies"]
P --> C["Clinical trials
Phase I, II, III"]
C --> R["Approval;
Phase IV
surveillance"]| Stage | What it decides | Computational contribution |
|---|---|---|
| Target identification and validation | Which protein to act on | Genomics and comparative genomics (targets present in a pathogen, absent in the host), expression and network analysis, druggability assessment |
| Hit finding | Which molecules bind at all | Virtual screening of compound libraries; pharmacophore and similarity searching |
| Hit to lead, lead optimisation | Which analogue is better | Docking and scoring, free-energy methods, QSAR, selectivity checks against related proteins |
| Preclinical | Whether it can be a drug | ADMET prediction, toxicity alerts |
Terms worth separating: a hit is any molecule showing activity in an assay; a lead is a validated, tractable hit with a usable structure–activity relationship; a candidate is the optimised compound taken into preclinical and clinical work.
Chemical and bioactivity databases
| Resource | Content |
|---|---|
| PubChem (NCBI) | Open archive of chemical substances and their bioassay results: Substance (SID), Compound (CID) and BioAssay (AID) records, with computed properties and cross-links |
| NCI resources | The US National Cancer Institute’s open compound collections and screening data, including the NCI-60 panel of sixty human tumour cell lines used for growth-inhibition profiling, and the NCI Open Database of structures available for research |
| ChEMBL (EMBL-EBI) | Manually curated bioactivities (\(IC_{50}\), \(K_i\), \(K_d\)) extracted from the medicinal-chemistry literature |
| DrugBank | Approved and investigational drugs with targets, pharmacology and interactions |
| ZINC | Commercially available compounds prepared in ready-to-dock 3D form |
| BindingDB | Measured binding affinities for protein–ligand pairs |
| PDBbind | PDB complexes paired with their measured affinities; used to train and test scoring functions |
| Cambridge Structural Database (CSD) | Small-molecule crystal structures: the source of standard bond lengths and geometries |
Chemical structures are exchanged as SMILES (a line notation, for example ethanol CCO), InChI and its hashed InChIKey (a canonical identifier), MOL/SDF files (atoms, bonds, optional 3D coordinates) and SMARTS (a pattern language for substructure queries, the chemical analogue of a regular expression).
Receptor–Ligand Interactions
Binding is a reversible equilibrium, \(\mathrm{R} + \mathrm{L} \rightleftharpoons \mathrm{RL}\):
$$K_d = \frac{[\mathrm{R}][\mathrm{L}]}{[\mathrm{RL}]}, \qquad \Delta G^{\circ} = RT\ln K_d = -RT\ln K_a$$A smaller \(K_d\) means tighter binding; \(K_d\) equals the free ligand concentration at which half the receptor is occupied. Since \(RT \approx 2.48\) kJ mol⁻¹ at 298 K, each tenfold gain in affinity is worth about 5.7 kJ mol⁻¹ (1.36 kcal mol⁻¹).
Binding free energy splits into enthalpy and entropy, \(\Delta G = \Delta H - T\Delta S\):
| Contribution | Physical origin |
|---|---|
| Hydrogen bonds, ionic and dipolar contacts | Directional, enthalpic; buried charges must pay a desolvation cost |
| Hydrophobic effect | Burying non-polar surface releases ordered water: largely entropic, and the main driver for most drugs |
| Van der Waals / shape complementarity | Many weak dispersion contacts; demands a close fit |
| Conformational entropy loss | Freezing rotatable bonds and side chains costs entropy, so rigidifying a ligand can improve affinity |
| Metal coordination, halogen bonds, π-stacking, cation–π | Specific contacts exploited in design |
Binding models: the rigid lock and key, induced fit (the site reshapes around the ligand) and conformational selection (the ligand captures one pre-existing conformation). Real sites show all three, which is why docking to a single rigid structure can mislead.
Pharmacological vocabulary (Part B favourites): agonist (binds and activates), partial agonist (submaximal response), inverse agonist (reduces basal activity), antagonist (blocks without activating; competitive at the same site, non-competitive/allosteric elsewhere), allosteric modulator (positive or negative). Potency is reported as \(IC_{50}\) or \(EC_{50}\); for a competitive inhibitor the concentration-independent constant is \(K_i\), related by the Cheng–Prusoff relation \(K_i = IC_{50}/(1 + [S]/K_m)\). Selectivity is the ratio of affinities for the intended target and an off-target; ligand efficiency is binding energy per heavy atom, \(LE = -\Delta G/N_{\text{heavy}}\), which stops chemists from buying potency with sheer size.
Structure-Based Drug Design (SBDD)
SBDD needs a 3D structure of the target: from X-ray crystallography, NMR or cryo-EM, or failing that a homology model or a predicted structure (with the caveats on the modelling page).
graph TD
A["Target structure
(PDB, model)"] --> B["Prepare: add H,
assign protonation,
remove waters, fix
missing loops"]
B --> C["Identify and
characterise the
binding site"]
C --> D["Dock a library:
poses + scores"]
D --> E["Rescore, cluster,
inspect interactions"]
E --> F["Synthesise and
assay the best"]
F --> G["New complex structure
→ next design cycle"]
G --> CMolecular docking
Docking has two parts: a search over the ligand’s position, orientation and conformation in the site, and a scoring function that ranks the poses.
| Search strategy | Examples |
|---|---|
| Systematic / incremental construction | DOCK, FlexX |
| Stochastic: genetic algorithms, Monte Carlo | AutoDock, GOLD, Glide (hierarchical), AutoDock Vina |
| Scoring function type | Basis | Weakness |
|---|---|---|
| Force-field based | Molecular-mechanics energies (LJ + Coulomb), sometimes with a solvation term | Poor treatment of entropy and desolvation |
| Empirical | Weighted sum of terms (H-bonds, hydrophobic contact, rotatable bonds) fitted to measured affinities | Only as good as the training set |
| Knowledge-based | Statistical potentials from the frequency of atom-pair contacts in known complexes | Biased by what has been crystallised |
| Machine-learned / consensus | Models trained on affinity data, or several functions combined | Needs careful validation against decoys |
Practical points exam questions test:
- Docking usually keeps the receptor rigid and the ligand flexible; ensemble docking or induced-fit protocols relax this.
- Scoring reproduces the pose far better than the affinity; rank ordering of different chemotypes is unreliable.
- Redocking a ligand from a known complex and measuring the RMSD to its crystal pose (commonly judged successful below 2 Å) validates the protocol.
- Water molecules in the site may be displaceable or essential; protonation states and tautomers change the result.
- MM-PBSA/GBSA and free-energy perturbation or thermodynamic integration give better energetics for a few compounds, at much higher cost.
Virtual screening and its metrics
Virtual screening ranks a library in silico so only the top fraction is assayed. Structure-based screening docks the library; ligand-based screening ranks by similarity or pharmacophore match. Performance is measured against a set of known actives mixed with presumed inactives (decoys):
$$\text{EF}_{x\%} = \frac{(\text{actives found in top } x\%)/(\text{compounds in top } x\%)}{(\text{total actives})/(\text{total compounds})}$$An enrichment factor of 10 means the selected fraction is ten times richer in actives than the whole library. ROC curves and AUC are also reported. Related ideas: fragment-based design (screen very small fragments with weak affinity by biophysical methods, then grow or link them, watching ligand efficiency), de novo design (build molecules inside the site, now often with generative models), and drug repurposing (screen approved drugs against a new target, so ADMET and safety are already known).
Ligand-Based Drug Design (LBDD)
Used when no structure of the target is available, but several active molecules are known. It rests on the similar property principle: structurally similar molecules tend to have similar activity.
Molecular descriptors and similarity
| Descriptor class | Examples |
|---|---|
| 0D/1D (constitutional) | Molecular weight, atom and ring counts, rotatable bonds, H-bond donors and acceptors |
| 2D (topological) | Connectivity indices, topological polar surface area (TPSA), fingerprints |
| Physicochemical | log P (octanol–water partition, lipophilicity), log D, \(pK_a\), solubility, molar refractivity |
| Electronic | Hammett σ constants, partial charges, dipole moment, HOMO–LUMO energies |
| Steric | Taft steric parameter \(E_s\), molar volume, Verloop sterimol parameters |
| 3D | Shape, surface area, CoMFA interaction fields, pharmacophore fingerprints |
Fingerprints encode substructures as bit strings; similarity between two fingerprints is usually the Tanimoto (Jaccard) coefficient:
$$T = \frac{c}{a + b - c}$$with \(a\) and \(b\) the bits set in each molecule and \(c\) the bits set in both. \(T = 1\) is identity; in practice \(T \ge 0.85\) on common fingerprints is treated as “quite similar”, but the threshold depends on the fingerprint.
Pharmacophores
A pharmacophore is the 3D arrangement of features required for activity, not a molecule and not a functional group: for example a hydrogen-bond donor, an aromatic ring centre and a positively ionisable centre at fixed distances. Features are typed as H-bond donor/acceptor, hydrophobic, aromatic, positive or negative ionisable.
- Ligand-based derivation: align several actives (flexible alignment of conformers) and keep the features they share; programs include Catalyst/HipHop-type methods, PHASE and LigandScout.
- Structure-based derivation: read the complementary features out of the binding site.
- Use: 3D database searching for new scaffolds (scaffold hopping), and as a filter before docking.
- Bioisosteric replacement swaps a group for another with similar properties to keep the pharmacophore while improving stability or permeability.
QSAR
Quantitative structure–activity relationship: a statistical model relating descriptors to activity, usually on a log scale.
$$\log\frac{1}{C} = a\,(\log P) + b\,\sigma + c\,E_s + d$$The classical Hansch (linear free-energy) approach uses physicochemical constants (log P, Hammett σ, Taft \(E_s\)); the Free–Wilson approach assigns each substituent at each position an additive contribution. Activity often depends parabolically on lipophilicity (\(\log 1/C = -a(\log P)^2 + b\log P + c\)): too polar and the molecule cannot cross membranes, too greasy and it is trapped in them or insoluble, so there is an optimum log P.
3D-QSAR places aligned molecules on a grid and correlates steric and electrostatic interaction fields with activity using partial least squares: this is CoMFA; CoMSIA uses similarity-index fields instead. Output is a contour map showing where bulk or charge helps or hurts.
Validating a QSAR model (a favourite Part C theme):
| Statistic | Meaning |
|---|---|
| \(R^2\) | Fit to the training set; always improves as descriptors are added, so it is not evidence of predictivity |
| \(q^2\) (\(Q^2\), cross-validated \(R^2\)) | Leave-one-out or leave-many-out internal prediction; \(q^2 > 0.5\) is a common minimum |
| \(R^2_{\text{pred}}\) on an external test set | The real test |
| y-randomisation | Shuffle activities and refit; a good model must then collapse |
| Applicability domain | Predictions are trusted only for molecules resembling the training set |
The rule of thumb is at least about five compounds per descriptor; otherwise chance correlation is likely.
Drug-Likeness and ADMET
A potent molecule is useless if it never reaches its target or is cleared or toxic. ADME(T) = absorption, distribution, metabolism, excretion and toxicity. Predicting these early is “fail fast, fail cheap”.
Drug-likeness filters
Lipinski’s rule of five (oral, passively absorbed drugs; derived by Lipinski and colleagues from compounds that had reached clinical trials): poor absorption is more likely when two or more of these hold.
| Property | Limit |
|---|---|
| Molecular weight | > 500 Da |
| log P | > 5 |
| Hydrogen-bond donors (sum of OH and NH) | > 5 |
| Hydrogen-bond acceptors (sum of N and O) | > 10 |
Related filters: Veber’s rules (rotatable bonds ≤ 10 and TPSA ≤ 140 Ų for good oral bioavailability); the rule of three for fragments (MW < 300, cLogP ≤ 3, donors ≤ 3, acceptors ≤ 3); PAINS filters that flag frequent-hitter substructures giving assay artefacts; lead-likeness limits that keep starting points small, since optimisation adds mass.
Known exceptions matter: natural products, antibiotics, peptides and actively transported compounds routinely break the rule of five, and the rule says nothing about potency or toxicity.
What ADMET prediction covers
| Property | Why it matters | Typical computational handle |
|---|---|---|
| Aqueous solubility | Dissolution limits absorption | log S models from descriptors |
| Permeability | Crossing gut epithelium; Caco-2 and PAMPA assays are the references | TPSA, log P, H-bond counts |
| Oral bioavailability (F) | Fraction of the dose reaching circulation | Rule-based plus trained models |
| Plasma protein binding | Only free drug acts | Lipophilicity-based models |
| Blood–brain barrier | Needed for CNS targets, avoided otherwise | Low TPSA and moderate log P favour entry; efflux by P-glycoprotein opposes it |
| Metabolism | Cytochrome P450 (notably CYP3A4, CYP2D6) oxidation in phase I, conjugation in phase II; inhibition or induction causes drug–drug interactions | Site-of-metabolism and CYP inhibition classifiers |
| Excretion, half-life | Dosing interval; \(t_{1/2} = 0.693\,V_d/CL\) | Clearance models |
| Toxicity | Attrition and withdrawal | Structural alerts, hERG channel blockade (cardiac QT risk), hepatotoxicity, mutagenicity (Ames) models |
Tools commonly named: SwissADME, pkCSM, admetSAR, ADMET Predictor, Derek-style expert systems; toxicity models are often (Q)SAR classifiers, and read-across from similar compounds is used in regulatory settings.
Memory Tricks
Don’t Confuse
| This | vs | That |
|---|---|---|
| SBDD: target structure required | vs | LBDD: known actives, no structure |
| Docking search: finds poses | vs | Scoring function: ranks them (the weaker half) |
| \(K_d\)/\(K_i\): equilibrium constants | vs | \(IC_{50}\): assay-dependent (Cheng–Prusoff links them) |
| Potency | vs | Ligand efficiency: potency per heavy atom |
| Pharmacophore: 3D feature pattern | vs | Functional group: specific chemistry |
| CoMFA (3D-QSAR): field-based, needs alignment | vs | Hansch QSAR: physicochemical constants, no alignment |
| \(R^2\): fit | vs | \(q^2\)/external \(R^2_{pred}\): predictivity |
| Rule of five: absorption risk flag | vs | Potency or safety: not covered by it |
| Competitive antagonist: same site | vs | Allosteric modulator: different site |
| Hit | vs | Lead: validated, optimisable, with an SAR |
Common Mistakes
Practice
All questions below are original practice questions written in CSIR NET style. They are not previous-year questions; this unit is new in the revised syllabus.
Level 1: Foundation
- Which approach is used when the 3D structure of the target is unknown but several active ligands are known?
- What does a pharmacophore describe?
- Name the four properties in Lipinski’s rule of five.
Answers
- Ligand-based drug design (similarity and pharmacophore searching, QSAR).
- The 3D arrangement of molecular features needed for activity.
- Molecular weight, log P, hydrogen-bond donors, hydrogen-bond acceptors.
Level 2: Part B Style
Q1 (practice). A ligand binds its receptor with \(K_d = 1\) nM at 298 K (\(RT = 2.48\) kJ mol⁻¹). The standard binding free energy is closest to:
- (a) −12 kJ mol⁻¹
- (b) −51 kJ mol⁻¹
- (c) +51 kJ mol⁻¹
- (d) −114 kJ mol⁻¹
Answer and explanation
(b). \(\Delta G^{\circ} = RT\ln K_d = 2.48 \times \ln(10^{-9}) = 2.48 \times (-20.72) \approx -51.4\) kJ mol⁻¹. Sign check: binding is favourable, so \(\Delta G\) is negative; (c) has the wrong sign and (d) would correspond to a far smaller \(K_d\).
Q2 (practice). A compound has MW 540 Da, cLogP 5.8, 2 hydrogen-bond donors and 6 acceptors. Regarding Lipinski’s rule of five:
- (a) it passes, because donors and acceptors are within limits
- (b) it has one violation, which the rule tolerates
- (c) it has two violations (MW and log P), flagging likely poor oral absorption
- (d) the rule cannot be applied without the \(IC_{50}\)
Answer and explanation
(c). MW > 500 and log P > 5 are two violations; the rule predicts poor absorption when two or more limits are exceeded. The rule uses only computed properties, so (d) is wrong, and potency is irrelevant to it.
Q3 (practice). Two molecules are compared with the same 2D fingerprint. Molecule 1 has 60 bits set, molecule 2 has 80 bits set, and 40 bits are set in both. The Tanimoto coefficient is:
- (a) 0.40
- (b) 0.50
- (c) 0.67
- (d) 0.80
Answer and explanation
(a). \(T = c/(a + b - c) = 40/(60 + 80 - 40) = 40/100 = 0.40\). Using 40/100 is the union in the denominator; dividing by either molecule alone (0.67 or 0.50) gives the Tversky-style asymmetric measures, not Tanimoto.
Q4 (practice). Which statement about docking scoring functions is correct?
- (a) Knowledge-based functions use statistical potentials derived from contacts observed in known complexes.
- (b) Empirical functions are derived purely from quantum-mechanical calculations.
- (c) Force-field scoring handles desolvation and entropy rigorously.
- (d) Scoring functions predict absolute binding affinities to within 1 kJ mol⁻¹.
Answer and explanation
(a). Empirical functions are weighted sums fitted to measured affinities, not QM results; force-field scoring treats solvation and entropy crudely; and absolute affinity prediction remains the weakest part of docking, with errors of several kJ mol⁻¹ or worse.
Level 3: Part C Style
Q1 (practice). A library of 100,000 compounds contains 200 known actives. A docking run is used to select the top 1% for assay, and 60 of the actives appear in that selection.
(i) Calculate the hit rate in the selection, the hit rate in the whole library, and the enrichment factor at 1%. (ii) How many actives would be missed? (iii) Give two reasons a well-enriched screen can still produce no usable lead.
Answer and worked solution
- Top 1% = 1,000 compounds, of which 60 are active: hit rate 6%. Library hit rate = 200/100,000 = 0.2%. \(\text{EF}_{1\%} = 0.06/0.002 = \mathbf{30}\).
- 200 − 60 = 140 actives missed (70% of them): good enrichment is not good recall, which is why the cut-off depends on how much assay capacity exists.
- For example: (a) the actives recovered may be weak, non-selective, or chemically intractable (PAINS-like frequent hitters, poor solubility); (b) scoring may rank a chemotype well for the wrong reason (a wrong pose, a displaced water, a wrong protonation state), so assay confirmation fails; (c) the enrichment was measured against decoys that are too easy to distinguish, overstating performance.
Q2 (practice). A series of analogues gives the QSAR equation
$$\log(1/C) = -0.35\,(\log P)^2 + 1.82\,\log P + 0.60\,\sigma + 3.10$$with n = 24, \(R^2 = 0.91\), \(q^2 = 0.78\).
(i) At what log P is activity predicted to be maximal? (ii) Predict \(\log(1/C)\) for an analogue with log P = 3.0 and σ = 0.23. (iii) What does the positive σ coefficient suggest? (iv) Comment on the statistics and on the limits of using this equation for a new analogue with log P = 7.
Answer and worked solution
- Differentiate: \(-0.70\log P + 1.82 = 0\), so log P = 2.6 gives maximum activity. The negative quadratic term is the usual parabolic lipophilicity dependence.
- \(-0.35 \times 9 + 1.82 \times 3 + 0.60 \times 0.23 + 3.10 = -3.15 + 5.46 + 0.138 + 3.10 = \mathbf{5.55}\).
- A positive coefficient on the Hammett constant means electron-withdrawing substituents (σ > 0) raise activity, hinting at an electronic requirement in the interaction.
- With 24 compounds and 3 descriptors the ratio is acceptable (about 8 per descriptor), and \(q^2 = 0.78\) indicates genuine internal predictivity rather than fit alone; an external test set and y-randomisation would still be needed. log P = 7 lies far outside the range the model was built on, so the prediction would be outside the applicability domain and the parabola would extrapolate an implausible collapse in activity.
Q3 (practice). A team has a validated bacterial enzyme target with a 2.0 Å crystal structure, and 15 known inhibitors from the literature spanning three scaffolds. Consider these plans:
(A) Dock a commercial library into the site after preparing the structure (hydrogens, protonation states, retained structural waters), then rescore and visually inspect the top poses. (B) Build a ligand-based pharmacophore from the 15 inhibitors and use it to search a 3D database for new scaffolds. (C) Accept the top-scoring docked compound as a lead without assay, since the scoring function is a free-energy calculation. (D) Check the selected compounds for rule-of-five violations, PAINS substructures and predicted hERG liability before buying them.
Which statements describe sound practice?
- (a) A, B and D only
- (b) A and C only
- (c) B, C and D only
- (d) A, B, C and D
Answer and worked solution
(a) A, B and D.
- (A) Sound: structure preparation, rescoring and human inspection of interactions are standard, because scores alone are unreliable.
- (B) Sound: with several actives in hand, a pharmacophore search complements docking and can find new scaffolds.
- (C) Wrong: docking scores are not free energies, and no computational result substitutes for an assay. The target’s homologue in the host should also be checked for selectivity.
- (D) Sound: early property and liability filters are cheaper than late failures.
Quick Revision Table
| Item | Fact |
|---|---|
| Pipeline | Target → hit → lead → optimisation → preclinical → Phase I–III → approval |
| Chemical databases | PubChem (SID/CID/AID), NCI collections and the NCI-60 cell-line panel, ChEMBL, DrugBank, ZINC, BindingDB, PDBbind, CSD |
| Structure formats | SMILES, InChI/InChIKey, MOL/SDF, SMARTS (substructure patterns) |
| Affinity | \(K_d\) small = tight; \(\Delta G^{\circ} = RT\ln K_d\); 10× affinity ≈ 5.7 kJ mol⁻¹ |
| \(IC_{50}\) vs \(K_i\) | Cheng–Prusoff: \(K_i = IC_{50}/(1 + [S]/K_m)\) |
| Binding forces | H-bonds and ionic (enthalpic, desolvation cost), hydrophobic effect (entropic, dominant), van der Waals, conformational entropy loss |
| Binding models | Lock and key, induced fit, conformational selection |
| Ligand efficiency | \(LE = -\Delta G/N_{\text{heavy}}\) |
| SBDD | Needs target structure; prepare → site → dock → rescore → assay → new structure |
| Docking | Search (systematic, genetic, Monte Carlo) + scoring (force-field, empirical, knowledge-based, ML); receptor usually rigid; redocking RMSD < 2 Å validates |
| Better energetics | MM-PBSA/GBSA, FEP, thermodynamic integration |
| Virtual screening | \(\text{EF}_{x\%}\); ROC/AUC; fragment-based, de novo, repurposing |
| LBDD | Similar property principle; descriptors 0D–3D; Tanimoto \(T = c/(a+b-c)\) |
| Pharmacophore | 3D features (donor, acceptor, hydrophobe, aromatic, ±ionisable); scaffold hopping; bioisosteres |
| QSAR | Hansch (log P, σ, \(E_s\)), Free–Wilson (additive substituents); parabolic log P optimum |
| 3D-QSAR | CoMFA (steric + electrostatic fields, PLS), CoMSIA |
| QSAR validation | \(R^2\) vs \(q^2 > 0.5\) vs external \(R^2_{pred}\); y-randomisation; applicability domain; ~5 compounds per descriptor |
| Rule of five | MW > 500, log P > 5, donors > 5, acceptors > 10; two or more = poor absorption likely |
| Other filters | Veber (rot. bonds ≤ 10, TPSA ≤ 140 Ų), rule of three (fragments), PAINS |
| ADMET | Solubility, permeability (Caco-2, PAMPA), bioavailability, protein binding, BBB and P-gp, CYP450 metabolism and interactions, clearance (\(t_{1/2} = 0.693V_d/CL\)), toxicity (hERG, Ames, hepatotoxicity) |
Key Takeaways
What’s Next
- Systems Biology, Data Science and Personalised Medicine — pathway and disease modelling, the network view of drug action.
- Molecular Modelling, Dynamics and Protein Structure Prediction — the force fields and structures docking depends on.
- Enzymes: Catalysis, Kinetics, Regulation and Isozymes — inhibition constants and mechanisms behind \(K_i\).
- Chapter overview and Quick Revision.